Today, organisations and governments worldwide are working towards the goal of achieving zero HIV transmission by 2030. The widespread adoption of Pre-Exposure Prophylaxis (PrEP) is seen as a cornerstone of achieving this objective. However, there are many barriers surrounding this HIV prevention strategy. Find out what over 3000 healthcare professionals think the main challenges are in achieving zero transmission by 2030 in our latest M3 Pulse results.
The battle against the transmission of HIV and AIDS has been ongoing since the early 1980s when the first case was reported, later evolving into a global public health threat. Since then, significant medical advancements and educational campaigns have played a crucial role in decreasing new HIV infections, improving treatment options, and reducing the stigma surrounding HIV/AIDS. Learn more about:
The United Nations’ Sustainable Development Goals (SDGs), specifically SDG 3 which focuses on health and well-being, have set a target to achieve zero HIV transmission by 2030.* This objective aligns with initiatives like the “Ending the HIV Epidemic in the U.S.”, launched in 2019, which aims to drastically reduce new HIV infections and AIDS-related deaths. These efforts particularly focus on marginalised communities, who face significant barriers to accessing HIV services due to the stigma surrounding HIV/AIDS and discrimination. The strategies adopted extend beyond medical interventions, incorporating community-led services that tackle broader social issues around HIV and AIDS.
As the 2030 deadline approaches, this initiative reflects a worldwide commitment to ending HIV transmission, emphasising the need for customised strategies and extensive community involvement.
In the past two decades, there has been a significant evolution in HIV/AIDS transmissions and related deaths worldwide.* As of 2022, the global population living with HIV has risen to approximately 39 million, up from 26.6 million in 2000. However, new infections have seen a substantial decrease, dropping 57% from 2.8 million in 2000 to 1.3 million in 2022.
Access to treatment has also improved remarkably. In 2022, 29.8 million people were receiving antiretroviral therapy (ART), an increase from 7.7 million in 2010. Despite these advances, the impact of HIV/AIDS remains significant, with 630,000 AIDS-related deaths in 2022.
These statistics highlight the progress made in combating HIV/AIDS, while also emphasising the ongoing global challenges in ensuring access to prevention, care, and treatment.
From First Reported Case in 1981 to Zero HIV Transmission in 2030
The history of HIV is marked by significant events and medical breakthroughs. In 1981, the first cases of AIDS were reported in the United States, predominantly among homosexual men, creating initial stigma. In 1983, French scientists Luc Montagnier and Françoise Barré-Sinoussi isolated the virus, initially named Lymphadenopathy-Associated Virus (LAV) and later renamed Human Immunodeficiency Virus (HIV).
Throughout the 1980s, HIV/AIDS became a global public health concern, which led to the launch of public awareness campaigns to reduce stigma and spread information. A breakthrough came in 1995 with the first effective antiretroviral treatment, marking significant progress in HIV/AIDS treatment.
The 2000s saw further advancements in HIV treatment. Highly Active Antiretroviral Therapy (HAART) transformed HIV from a fatal disease to a manageable chronic condition. Global initiatives like the Global Fund and PEPFAR began providing medication to low and middle-income countries.
Recent years have seen improvements in antiretroviral therapy, with more effective and fewer side effects. Pre-Exposure Prophylaxis (PrEP), a preventive treatment for high-risk HIV-negative individuals, was approved by the FDA in 2012. PrEP drastically reduces HIV infection risk, marking a shift from behaviour-based prevention to a biomedical approach.
In 2021, the FDA approved a new PrEP in the form of a long-acting injectable. This marked a pivotal development in HIV prevention, shifting from the need for taking pills every day to just six injections per year. This significant change is expected to improve patient adherence and convenience, thereby enhancing the effectiveness of HIV prevention strategies. Such advancements are important in the ongoing global fight against HIV, contributing to prevention efforts, treatment, and the ultimate goal of achieving zero HIV transmission by 2030.
Challenges Around HIV Prevention Strategies
HIV prevention strategies face several key challenges that impact their effectiveness. These challenges include:
1. Stigma and Misconceptions around HIV: Stigma surrounding HIV/AIDS significantly impacts both prevention and treatment. Misconceptions about how the condition is transmitted contribute to this stigma, leading to discrimination against those living with the virus. This can deter individuals from getting tested or seeking treatment.
2. Awareness and Diagnosis: There is a critical need to increase awareness and early diagnosis of HIV. Many individuals living with this condition are unaware of their status, which hinders efforts to control the spread of the virus and delays treatment initiation.
3. Ongoing HIV Treatment: Many people diagnosed with this condition do not receive or adhere to ongoing treatment. Consistent treatment is crucial not only for the health of the individual but also for reducing the risk of transmission to others.
4. Social and Economic Disparities: HIV disproportionately affects marginalised and economically disadvantaged communities. These groups often face barriers accessing healthcare, including testing and treatment, due to factors like poverty, discrimination, and lack of education.
5. Financial and Resource Limitations: The combat against HIV/AIDS is often constrained by financial and resource limitations. This can lead to insufficient funding for prevention programmes, research, and treatment access, particularly in low and middle-income countries.
6. Complacency: With the advancements in HIV treatment, there is a growing complacency about the virus. This can lead to a decrease in preventive behaviours and a misunderstanding of the ongoing risk of HIV transmission.
These challenges highlight the need for multifaceted and tailored strategies to achieve zero HIV transmission by 2030. Addressing these issues requires a combination of medical, social, and economic interventions, alongside education and awareness campaigns tailored to various demographics and communities.
M3 Pulse Results: Healthcare Professionals Take on Achieving Zero New Transmissions by 2030
In December 2023, our M3 Pulse survey questioned 3034 healthcare professionals about potential obstacles to achieving zero new HIV transmissions by 2030. The results revealed several key challenges by our M3 members, which could potentially impact the realisation of this goal. This is particularly relevant in relation to one of the main HIV prevention strategies, which is the widespread adoption of injectable PrEP.
See the full M3 Pulse survey results below and let us know what your thoughts are on this topic in the comment section below.
*Please select your language
/>
M3 Pulse is a one-question online survey we conduct every month with our M3 panel members. It´s a fun and easy way to share your opinions about trending healthcare topics with a global community of healthcare professionals. If you want to participate in this month´s M3 Pulse, register and join the M3 panel today.
The most significant challenge noted was the widespread misconceptions about PrEP. About 26% of healthcare professionals felt PrEP is often wrongly linked with irresponsible sexual behaviour by both the public and their peers in healthcare, which could discourage its use. Close behind, 23% of respondents expressed concern that apprehension about the side effects of PrEP medications might lead to hesitancy in the population.
The stigma surrounding the use of PrEP also emerged as a substantial barrier, with 19% of those surveyed pointing out that the fear of being associated with an HIV-positive status could deter individuals from using PrEP.
Financial considerations, including the cost of PrEP, were identified by 16% of healthcare professionals as a potential obstacle, suggesting the expense could be a limiting factor for widespread adoption. Additionally, 14% highlighted there are significant obstacles within healthcare provision itself; inadequate human and financial resources at provider and facility levels could hinder the effective roll-out of PrEP.
This survey reflects the complexity of implementing public health initiatives like PrEP to achieve the objective of zero HIV transmission by 2030 and underscores the need for targeted HIV prevention strategies to address these multifaceted barriers.
As a healthcare professional, what are your thoughts on the goal of achieving zero transmissions by 2030? Leave a comment in the section below and share this article with a colleague on social media.
Take Part in Market Research
Take part in the next M3 Pulse and get rewarded when you share your opinions in paid market research studies
You Might Be Interested in:
Market Research in Healthcare: a Gateway to Satisfied Patients
Market research in healthcare is an important component when looking to improve patient experience, patient outcomes, and their overall satisfaction with their treatment.
Find out why.
Paid Medical Surveys for Physicians, M3´s “How To” Guide
Can paid medical surveys for physicians serve as a secondary income stream? The six most commonly asked questions about market research in healthcare
latest posts
How COVID-19 Affects the Skin: From Acute Rashes to Long-Term Dermatological Sequelae
The BMJ review shows COVID-19 affects the skin, causing cutaneous manifestations from transient inflammatory rashes to severe lesions.
Nasal Swab Identifies Early Alzheimer’s Biological Markers Before Symptom Onset
Nature Communications study shows a nasal swab can detect Alzheimer’s biological markers for early Alzheimer’s detection.
Researchers Develop Modified Antibiotic 60 Times More Effective Against H. pylori
Nature Microbiology study from Technical University of Munich shows a modified antibiotic is far more effective against H. pylori.
Join Today
Panel Members